Objective. To investigate the expression of kinesin family member 20A (KIF20A) in bladder cancer, the effect of KIF20A on the proliferation and metastasis of bladder cancer cells, and the effect of KIF20A expression on the prognosis of bladder cancer patients.Methods. Bladder cancer tissue and its adjacent tissues were collected from tumour patients. The mRNA and protein expression levels of KIF20A in the tissue samples were detected by qRT-PCR and western blot. Immunohistochemical (IHC) staining was used to identify the expression and distribution of KIF20A proteins in the tissue samples. The relationship between the KIF20A expression and the clinical pathology of bladder cancer was analysed. The effect of the differential expression of KIF20A on the prognosis of patients with bladder cancer was analysed by the TCGA database. The plasmid was transfected into the bladder cell lines T24 and 5637 to construct two stable cell lines with knocked down KIF20A. The effect of KIF20A expression on the proliferation and invasion of T24 and 5637 bladder cells was explored in vitro using the abovementioned stable cell lines. The effect of the KIF20A expression on the proliferation of bladder cancer cells was evaluated by a mouse xenograft model.Results. The expression of KIF20A was significantly higher in the bladder cancer tissues than in the adjacent control tissues. The expression of KIF20A was significantly associated with the degree of pathological differentiation of bladder cancer. Patients with a higher expression of KIF20A had a higher tumour grade and a more advanced stage. The mean survival of patients with a high KIF20A expression was significantly lower than the mean survival of patients with a low KIF20A expression. The in vitro experiments demonstrated that the knockdown of KIF20A significantly inhibited T24 and 5637 cell proliferation and invasion. The in vivo experiments showed that the knockdown of KIF20A significantly inhibited the proliferation of the bladder tumours.Conclusion. KIF20A promotes the proliferation and metastasis of bladder cancer cells. Bladder cancer patients with a high KIF20A expression have a worse tumour differentiation and a poor prognosis. KIF20A may become an independent factor that affects the prognosis of bladder cancer patients and a therapeutic target for bladder cancer.

INTRODUCTION: Numerous studies have evaluated the association between the matrix metalloproteinase 9 (MMP-9) and prostate cancer (PCa) risk. However, these studies have yielded conflicting results. EVIDENCE ACQUISITION: A comprehensive search was conducted through researching MEDLINE, PubMed, Web of Science, and EMBASE, and a total of 10 studies including 1059 cases were included on the basis of inclusion criteria. EVIDENCE SYNTHESIS: A meta-analysis was performed to obtain a summary of estimated odds ratios (ORs) and 95% confidence intervals (CIs) of MMP-9 for PCa, with attention to study quality and publication bias. MMP-9 by immunohistochemistry was significantly associated with increased diagnosis of PCa (OR=7.91; 95% CI: 5.27-11.89; P<0.00001). Subgroup-analysis showed that findings did not substantially change when only Caucasians or Asians (OR=5.87; 95% CI: 3.38-10.20; P<0.00001) or (OR=11.80; 95% CI: 6.60-21.08; P<0.00001) were considered. There was also no significant publication bias observed. CONCLUSIONS: Our findings provide further evidence that the expression of MMP-9 contribute to PCa risk. MMP-9 protein overexpression was found in prostate cancers, low expression in any of the normal tissues or in benign prostatic tissue. MMP-9 is potentially an important prostate tumor marker.

Numerous studies have evaluated the association between the matrix metalloproteinase 9 (MMP-9) and prostate cancer (PCa) risk. However, these studies have yielded conflicting results.A comprehensive search was conducted through researching MEDLINE, PubMed, Web of Science, and EMBASE, and a total of 10 studies including 1059 cases were included on the basis of inclusion criteria.A meta-analysis was performed to obtain a summary of estimated odds ratios (ORs) and 95% confidence intervals (CIs) of MMP-9 for PCa, with attention to study quality and publication bias. MMP-9 by immunohistochemistry was significantly associated with increased diagnosis of PCa (OR=7.91; 95% CI: 5.27-11.89; Pu003c0.00001). Subgroup-analysis showed that findings did not substantially change when only Caucasians or Asians (OR=5.87; 95% CI: 3.38-10.20; Pu003c0.00001) or (OR=11.80; 95% CI: 6.60-21.08; Pu003c0.00001) were considered. There was also no significant publication bias observed.Our findings provide further evidence that the expression of MMP-9 contribute to PCa risk. MMP-9 protein overexpression was found in prostate cancers, low expression in any of the normal tissues or in benign prostatic tissue. MMP-9 is potentially an important prostate tumor marker.

Renal Oncocytomas and renal cell carcinomas (RCCs) share a common phenotype. This makes it very difficult to differentiate between the two tumors. Here, this study was to confirmed and expanded the findings that CK7 as a promising tool differentiate RCC from Oncocytomas across various geographic regions. A systematic search of databases was carried out and other relevant articles were also identified. Then the meta-analyses were conducted for 1,711 participants according to the standard guidelines. A total of 21 studies were included on the basis of inclusion criteria. CK7 by IHC was significantly associated with increased diagnosis of RCC (OR=10.64; 95% CI, 7.44-15.23; P=0.0001). Subgroup-analysis showed that findings didn't substantially change when only Caucasians or Asians (OR=10.58; 95% CI, 6.97-16.07; P < 0.01 or OR=10.83; 95% CI, 5.39-21.74; P=0.004) were considered. There was also no significant publication bias observed. Our findings provide further evidences that the expression of CK7 contribute to differentiate RCC from Oncocytomas. CK7 protein overexpression was found in RCC, low expression in any of Oncocytomas. CK7 is potentially an important renal tumor marker.